Published in Hepatitis Weekly, December 4th, 2000
The data were presented at the 51st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Coviracil is a nucleoside analogue that Triangle is also developing for the treatment of HIV infection.
The 24-week, double-blind, randomized trial compared the anti-HBV activity of Coviracil in doses of 25 mg once daily (qd), 100 mg qd, and 200 mg qd. Ninety eight patients with chronic HBV infection participated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.